STEPping down diuretic therapy with semaglutide in obesity-related heart failure with preserved ejection fraction: decongestion or disease modification?-Reference-Cited by-同舟云学术

STEPping down diuretic therapy with semaglutide in obesity-related heart failure with preserved ejection fraction: decongestion or disease modification?

Published:2024-07-26 Issue:35 Volume:45 Page:3270-3273
ISSN:0195-668X
Container-title:European Heart Journal
language:en
Short-container-title:

Author:

Ostrominski John W¹²^ORCID,Chatur Safia¹,Vaduganathan Muthiah¹^ORCID

Affiliation:

1. Cardiovascular Division, Brigham and Women’s Hospital and Harvard Medical School , 75 Francis St, Boston, MA 02115 , USA

2. Division of Endocrinology, Diabetes and Hypertension, Brigham and Women’s Hospital and Harvard Medical School , Boston, MA , USA

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/eurheartj/article-pdf/45/35/3270/59118036/ehae410.pdf

Reference16 articles.

1. Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment;Boorsma;Nat Rev Cardiol,2020

2. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC;McDonagh;Eur Heart J Fail,2022

3. Adverse renal response to decongestion in the obese phenotype of heart failure with preserved ejection fraction;Reddy;J Card Fail,2020

4. Sacubitril/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON-HF trial;Chatur;Eur J Heart Fail,2023

5. Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial;Chatur;Eur Heart J,2023